6 August 2020Effects of messaging on public support for drug consumption rooms in Scotland, UKSumnall et al. find support for DCRs can increase when public concerns and potential benefits are addressed.
6 August 2020Аssessment of the sustainability of the opioid agonist therapy programme in the context of transition from donor support to domestic funding in BelarusEHRA makes recommendations for the adoption of opiate agonist therapy programmes in Belarus.
5 August 2020EU Agenda and Action Plan on Drugs 2021-2025The EU outlines its priorities in relation to drug markets for the next four years.
5 August 2020Medicinal use of psilocybin: Reducing restrictions on research and treatmentASI and CDPRG urge British authorities to reschedule psilocybin to facilitate research and treatment.
5 August 2020Аssessment of the sustainability of the opioid agonist therapy programme in the context of transition from donor support to domestic funding in TajikistanEHRA makes recommendations for the adaption of opiate agonist therapy programmes in light of COVID-19 in the Republic of Tajikistan.
5 August 2020How Structural Violence, Prohibition, and Stigma Have Paralyzed North American Responses to Opioid OverdoseTyndall and Dodd discuss the roots of policymakers' inaction to end prohibition and, in turn, the overdose crisis.
5 August 2020Preliminary findings of the impact of COVID-19 on drugs crypto marketsBergeron et al. look into the correlation between COVID-19 lockdowns and the disruption of drug cryptomarkets.
5 August 2020Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemicSchlosser and Harris discuss challenges and innovation by peers and other harm reductionists in response to disruptions caused by COVID-19.
4 August 2020The Good Samaritan Drug Overdose Act: The good, the bad and the ineffectiveThe Canadian HIV/AIDS Legal Network evaluate the law's impact in terms of awareness and reliance on medical assistance.
3 August 2020Closing doors: The exclusion of civil society at the ‘topical meetings’ of the UN Commission on Narcotic DrugsIDPC explains how civil society has been excluded from the newly-created ‘topical meetings' on the WHO cannabis re-scheduling recommendations, and why this departs from recent progress on openness and civil society participation.
27 July 2020The 2020 Commission on Narcotic Drugs - Report of ProceedingsIDPC provides an overview of the 63rd session, highlighting the fault lines underlying an ever-eroding 'Vienna consensus'.
27 July 2020Technical brief: Harm reduction for people who use drugsThis brief by the Global Fund explains how to ensure that harm reduction interventions are in line with international standards and guidance.